Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.

The Journal of antimicrobial chemotherapy - 1 Sept 2017

Buil J B, Rijs A J M M, Meis J F, Birch M, Law D, Melchers W J G, Verweij P E

Abstract excerpt

Background: F901318 is a new antifungal agent with a novel mechanism of action with activity against Aspergillus species. We investigated the in vitro activity of F901318 against a collection of Aspergillus isolates. Methods: A total of 213 Aspergillus isolates were used in this study. A total of 143 Aspergillus fumigatus sensu stricto isolates were used, of which 133 were azole resistant [25 TR34/L98H; 25...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Aspergillus
Share to Aspergillus fumigatus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Itraconazole

Share to Nitriles

Share to Pyrroles

Share to Triazoles

Share to Voriconazole

Source

Identifiers

PMID: 28605488
DOI: 10.1093/jac/dkx177

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.PMID 28605488Read ↗

In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms.Semantic proximity Read ↗

Cryptic species and azole resistance in the Aspergillus niger complex.Semantic proximity Read ↗

Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complexSemantic proximity Read ↗

Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.Semantic proximity Read ↗

Luliconazole, a New Antifungal, vs Amphotericin B, Voriconazole, Posaconazole and Caspofungin against Clinical and Environmental <i>Aspergillus</i> Nigri ComplexSemantic proximity Read ↗

In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in ChinaSemantic proximity Read ↗

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).Semantic proximity Read ↗

Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolatesSemantic proximity Read ↗

Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.Semantic proximity Read ↗

Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds.Semantic proximity Read ↗

In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.Semantic proximity Read ↗

Molecular Identification of <i>Aspergillus</i> Species Collected for the Transplant-Associated Infection Surveillance NetworkSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.